Webinar – Treatment Optimization in Locally Advanced & Metastatic Pancreatic Cancer-Tailored Patient Approach with Targeted Therapy
Prof. Dr. Dirk Strumberg, Oncologist in Marien Hospital Herne, Germany
Similar Posts
Patent Granted for “Treatment of Patients Diagnosed with Pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” in Russia
ByInnokeys
New patent is granted with the title of “Treatment of Patients Diagnosed with Pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR”…
May 2015 : Innokeys Pte Ltd at Asia Biotech Invest 2015
ByInnokeys
Kowloon, Hong Kong (May 20, 2015) – Innokeys Pte Ltd attended the Asia Biotech Invest 2015 as one of the presenting companies….
Webinar – Current Treatment of Locally Advanced Head and Neck Cancer and The Result of Randomized Phase III Study of Nimotuzumab in Locally Advanced Head and Neck Cancer
ByInnokeys
Speakers: 1. Prof. Iyer Narayanan Gopalakrishna, Head and neck surgeon in National Cancer Centre and Singapore General Hospital 2. Prof. Dr. Kumar…
Webinar – Clinical Experience of Using Nimotuzumab in Nasopharyngeal Cancer
ByInnokeys
Speaker: Dr. dr. Andhika Rachman, Sp.Pd-KHOM from MRCCC Siloam Hospital Indonesia
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab
ByInnokeys
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine. The…
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
ByInnokeys
MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ – YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys…